Irinotecan

Cas No.:	97682-44-5
Chemical Name:	Irinotecan
Synonyms:	Irinotecan;1,4'-bipiperidine-1'-carboxylic acid (s)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester;(+)-Irinotecan;CAMPTOSAR;Irinotecan,free base（CPT-11, Camptothecin 11,U-101440E,DQ-2805）;+-Irinotecan;7-ethoxyxanthone-3-carboxylic acid;9H-Xanthene-3-carboxylic acid,7-ethoxy-9-oxo;CPT-11;1,4'-Bipiperidine-1'-carboxylic acid (S)-4,11-diethyl-3,4,12,14- tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester;Irinotecanum;Irinotecanum [INN-Latin];Irinotecan lactone;Campto;Irinotecan mylan;Irinophore C;Irinotecan [INN:BAN];Onivyde;C33H38N4O6;AK163712;product-irinotecan
SMILES:	O(C1C([H])=C([H])C2=C(C=1[H])C(C([H])([H])C([H])([H])[H])=C1C(C3=C([H])C4=C(C([H])([H])OC([C@@]4(C([H])([H])C([H])([H])[H])O[H])=O)C(N3C1([H])[H])=O)=N2)C(N1C([H])([H])C([H])([H])C([H])(C([H])([H])C1([H])[H])N1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C
Formula:	C33H38N4O6
M.Wt:	586.678
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	Irinotecan is a water soluble topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex.
In Vivo:	Irinotecan (CPT-11, 5 mg/kg) significantly inhibits the growth of tumors by intratumoral injection daily for 5 days, on two consecutive weeks in rats, and such effects also occur via continuous intraperitoneal infusion by osmotic minipump into mice. However, Irinotecan (10 mg/kg) shows no effect on the growth of tumor by i.p[1]. Irinotecan (CPT-11, 100-300 mg/kg, i.p.) apparently suppresses tumor growth of HT-29 xenografts in athymic female mice by day 21. The two groups of Irinotecan (125 mg/kg) plus TSP-1 (10 mg/kg per day) or Irinotecan (150 mg/kg) in combination TSP-1 (20 mg/kg per day) are nearly equally effective and inhibit tumor growth 84% and 89%, respectively, and both are more effective than Irinotecan alone at doses of 250 and 300 mg/kg[3].
In Vitro:	Irinotecan is a topoisomerase I inhibitor. Irinotecan inhibits the growth of LoVo and HT-29 cells, with IC50s of 15.8 ± 5.1 and 5.17 ± 1.4 μM, respectively, and induces similar amounts of cleavable complexes in both in LoVo and HT-29 cells[2]. Irinotecan suppresses the proliferation of human umbilical vein endothelial cells (HUVEC), with an IC50 of 1.3 μM[3].